Plan de negocios para la producción y comercialización de un medicamento Hepatoprotector de venta libre

The present business plan focuses on proposing a business idea focused on the pharmaceutical market, specifically with the commercialization of a vitamin supplement focused on the improvement of the liver functions in the human. This vitamin supplement has the name of heparin, which contains a high concentration of silymarin, coenzyme Q 10 and all the vitamins of the B complex. The production of heparin is performed through the figure of outsourcing with the company Farmacid, which is a specialist in the development of medicines and vitamin supplements for various brands in the country. The negotiation with the company Farmacid is carried out under the figure of "full cost" which includes the manufacture of heparin, storage the finished product and distribution to the chains of pharmacies in the country. By carrying out this operational management Farmacid charges a fee that varies according to the projection of demand, is assumed as a variable cost of production. The commercial management is carried out by the company, through the promotion of the vitamin supplement with a combination of traditional and digital marketing actions. In addition, the organizational structure takes into account the recruitment of medical visitors, who will be responsible for the promotion of heparin with medical professionals. Based on the business idea outlined above, the initial investment has a value of 156,829.09 dollars, which includes the acquisition of goods and furniture for company personnel, constitution expenses, health records and operating and capital permits which contains the cash reserve for staff salary expenses and initial marketing. For the financial evaluation, three scenarios are constructed, taking into account the projection of the demand based on the current demand of the brands that have presence in the market. In the expected scenario, 35,456 boxes of 20 heparin units are planned to be marketed through pharmacy chains during year 1. Valuation criteria determine that the project has a Net Present Value of 48,983 dollars and Internal Rate of Return 40.56 percent, this determines that the project is viable.

• Hovedforfatter: Aráuz Rodríguez, Jorge Enrique (author)
• Format: masterThesis
• Sprog: spa
• Udgivet: 2018
• Fag: PLANEACIÓN EMPRESARIAL; EMPRESAS, INDUSTRIAS Y SERVICIOS; INDUSTRIA FARMACÉUTICA; MEDICAMENTOS
• Online adgang: http://dspace.udla.edu.ec/handle/33000/8415